Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Hematology ; (12): 19-22, 2005.
Artigo em Chinês | WPRIM | ID: wpr-229891

RESUMO

<p><b>OBJECTIVE</b>To study the expression of recombinant human SCF-TPO fusion protein and its biological function.</p><p><b>METHODS</b>Four primers were designed according to known sequences of TPO and SCF. The functional amino acid domains of TPO and SCF were amplified by RT-PCR from fetus hepatocytes, respectively. The expression plasmid pET32a/SCF-TPO was constructed by VOE gene fusion technique and expressed in E. coli BL21(DE3) plysS as inclusion body after isopropyl-beta-D-1-thiogalactopyranoside (IPTG) induction. The fusion protein was tested by SDS-PAGE and Western blot. The biological functions of SCF-TPO fusion protein in MO7e cells was investigated by MTT method after purification with metal chelating chromatography.</p><p><b>RESULTS</b>The high expression SCF-TPO fusion protein was obtained, reaching up to 30% of the total cellular protein. Western blot verified the correct fusion expression and MTT results showed the growth promoting effect of the SCF-TPO fusion protein on MO7e cells, with a higher promoting activity at 100 ng/ml.</p><p><b>CONCLUSIONS</b>Expressed SCF-TPO fusion protein after renaturation has biological activity in promoting the proliferation of MO7e cells.</p>


Assuntos
Humanos , Western Blotting , Linhagem Celular Tumoral , Proliferação de Células , Sobrevivência Celular , Genética , Fisiologia , Clonagem Molecular , Eletroforese em Gel de Poliacrilamida , Escherichia coli , Genética , Vetores Genéticos , Proteínas Recombinantes de Fusão , Genética , Metabolismo , Fisiologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fator de Células-Tronco , Genética , Metabolismo , Fisiologia , Trombopoetina , Genética , Metabolismo , Fisiologia
2.
Journal of Experimental Hematology ; (6): 825-828, 2004.
Artigo em Chinês | WPRIM | ID: wpr-347853

RESUMO

The objective was to identify some biochemical and physical properties for fusion protein IL6D24-PE40KDEL. Edman degradation, SDS-PAGE, peptide mass fingerprinting, Western blot and MTT were used for identification of the protein. The results showed that the sequence of N-terminus is Met-Ile-Asp-Lys-Gln-Ile, Met was added because of prokaryotic expression system; Western blot revealed that the purified protein could react with IL6 and PEA antibody. The purified protein IL6D24-PE40KDEL could kill the multiple myeloma cell lines U266 expressing high affinity IL6R, but it could not kill the cell lines CEM which not expressed IL6R; The molecular weight was 58.7 kD measuring by SDS-PAGE; peptide mass fingerprinting (PMF) confirmed that the construction of IL6D24-PE40KDEL was correct. A novel protein by Peptident database in EXPASY web site was identified. In conclusion, IL6D24-PE40KDEL is a new targeting protein with bioactivity of specific killing effect.


Assuntos
Humanos , ADP Ribose Transferases , Química , Metabolismo , Farmacologia , Sequência de Aminoácidos , Western Blotting , Linhagem Celular Tumoral , Sobrevivência Celular , Relação Dose-Resposta a Droga , Exotoxinas , Química , Metabolismo , Farmacologia , Interleucina-6 , Química , Metabolismo , Farmacologia , Dados de Sequência Molecular , Pseudomonas aeruginosa , Genética , Metabolismo , Proteínas Recombinantes de Fusão , Química , Metabolismo , Farmacologia , Análise de Sequência de Proteína , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
3.
Chinese Journal of Applied Physiology ; (6): 380-384, 2004.
Artigo em Chinês | WPRIM | ID: wpr-330089

RESUMO

<p><b>AIM</b>Design, construction, expression in E coli and protein characteristics prediction of bimolecular thrombopoietin (T-T) with more stability, efficiency, and lower toxicity.</p><p><b>METHODS</b>The expression vectors of TPO and T-T, pET32 a(+)/TPO and pET32 a (+)/T-T, had been constructed by molecular cloning methods. Then, they were expressed in host bacterium. Their products were identified by Western blot. The protein characteristics, such as second structure, antigenicity, hydrophilicity, flexibility and isoelectric point, were predicted by DS Gene and Protscale software.</p><p><b>RESULTS</b>The expressing vectors pET32a(+)/TPO and T-T were constituted correctly and expressed in origami (DE3), and their expression efficiency were more than 40 percent of total protein. T-T was identified correctly by Western blot. DS Gene and Protscale software predict the protein characteristics of TPO sequences in T-T molecule were no change, there was high flexibility in the linker domain. But two amino acids in T-T molecule have been mutated, and an insert fragment with 34 amino acids following the linker had antigenicity, hydrophilicity, and beta-sheet structure.</p><p><b>CONCLUSION</b>We have constructed correctly and expressed T-T with high level in E Coli. Protein characteristics prediction of T-T accords with our design.</p>


Assuntos
Clonagem Molecular , Escherichia coli , Expressão Gênica , Vetores Genéticos , Proteínas Recombinantes de Fusão , Genética , Trombopoetina , Genética
4.
Journal of Experimental Hematology ; (6): 184-187, 2001.
Artigo em Chinês | WPRIM | ID: wpr-354996

RESUMO

An inevitable trend for the development of new treatment of leukemia is to use targeted strategy. IL-6/IL-6R is important one of the cytokine receptor targeted treatment systems. Many malignant cells, including multiple myeloma, prostate carcinoma and leukemia etc., have been shown to express IL-6R. Leukemia cells, especialy in U937, TF1, KG1 cell lines highly express the high affinity IL-6R. IL-6 recombinant toxin is cytotoxic in vitro to leukemia cell expressing high affinity IL-6R; in vivo the fusion toxin can result the reduction of leukemic cell load in animal leukemia model but have no effect on normal hematopoiesis in non-leukemic animal. On the basis of these pre-clinical studies, IL-6 recombinant toxin my become novel drug for the treatment of leukemia and cancer in future.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA